TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

NCT06353360 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

DEVICE: Tumor Treating Fields
DRUG: Tislelizumab
DRUG: Temozolomide (TMZ)

Sponsor

Jiangsu Healthy Life Innovation Medical Technology Co., Ltd